Hepatocellular Carcinoma
Conditions
Keywords
NKCELL
Brief summary
To see the safety and efficacy of injecting MG4101 as a secondary treatment after curative liver resection on the patient with advanced HCC who has high risk of recurrence.
Detailed description
To see the safety and efficacy of injecting MG4101(Ex vivo expanded allogeneic NK cell) as a secondary treatment after curative liver resection on the patient with advanced HCC who has high risk of recurrence.
Interventions
BIOLOGICALMG4101
Ex vivo expanded allogeneic NK cell
Sponsors
Samsung Medical Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to 69 Years
Healthy volunteers
No
Inclusion criteria
1. Under the age of 20 to 69 years of age 2. Child-pugh class A 3. After curative liver resection, diagnosed hepatocellular carcinoma 4. Modified UICC staging : stage 3 5. the women who is childbearing age, agree to maintain adequate contraception measure during clinical trial period. 6. Agreed to participate in this clinical trial, agree to the subject person or legal representative who agrees in writing
Exclusion criteria
1. Less than 20 years old, 70 years old or older 2. Metastasis of hepatocellular carcinoma with external parties surgery 3. who had Rupture of hepatocellular carcinoma (HCC) 4. Hepatocellular carcinoma treated with radiofrequency surgery therapeutics (Radiofrequency ablation, RFA), the carotid artery chemical embolization (Transarterial chemoembolization, TACE), underwent radiation therapy, such as topical therapeutics 5. suspected serious infection 6. Who have severe cardiovascular disease (coronary artery disease requiring treatment, heart failure, arrhythmias, myocardial infarction, etc.) 7. Pregnant, planning a pregnancy or breast-feeding women 8. Autoimmune Disease 9. Those who Latest within four weeks of administration of systemic steroids (However, inhalation, intranasal corticosteroids and topical administration of corticosteroids and short-time administration of a blood transfusion, if such reasons are excluded) 10. Latest within four weeks of taking immunosuppressive drugs such as Cyclosporine A 11. Within the last 5 years diagnosed with liver cancer and other malignancies 12. Investigator did not complete or the effectiveness or safety of pharmaceutical products of this clinical trial evaluation for any medical condition that can interfere with characters judged
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Disease free survival, DFS | Disease free survival for 1year | As of Date for allocation to survival and recurrence of the incident or death from any cause is defined as. 1 year disease-free survival was calculated using Kaplan-Meier estimation and 95% confidence interval and median survival (median survival time) are presented. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Changes in tumor markers | Changes in tumor markers. to be specific, alpha-fetoprotein(AFP), protein induced by vitamin K absence- II(PIVKA-II) | Basaline(V2) at each visit compared (V6, V8, V9, V10) with respect to variation in average by descriptive statistics (mean, standard deviation, median, minimum, maximum) and presented, in comparison to the group in order Paired t-test or the Wilcoxon's signed rank test for analysis. |
| Overall survival, OS | Overall survival, OS at the end point of clinical trial | As of Date for allocation to survival, and the incident was defined as death from any cause. 1 year overall survival was calculated using Kaplan-Meier estimation and 95% confidence interval and median survival (median survival time) are presented. |
Countries
South Korea
Outcome results
None listed